signaling lymphocytic activation molecule family member 1


Summary: A 70-kDa SLAM family receptor that consists of an extracellular IMMUNOGLOBULIN-LIKE DOMAIN and an IMMUNOGLOBULIN C2-SET DOMAIN. It is expressed primarily by THYMOCYTES and activated T-LYMPHOCYTES, as well as by MACROPHAGES and DENDRITIC CELLS. It binds SLAMF1 receptors on other cells to mediate T-cell maturation and proliferation. It is also a receptor for the MEASLES VIRUS.

Top Publications

  1. RACANIELLO V. Virology. An exit strategy for measles virus. Science. 2011;334:1650-1 pubmed publisher
  2. Tornack J, Kawano Y, Garbi N, Hämmerling G, Melchers F, Tsuneto M. Flt3 ligand-eGFP-reporter expression characterizes functionally distinct subpopulations of CD150+ long-term repopulating murine hematopoietic stem cells. Eur J Immunol. 2017;47:1477-1487 pubmed publisher
    ..Thus, FACS-enrichment of Flt3/ Flt3L-eGFP-reporter negative, Lin- CD150+ CD48- EPCR+ CD41+ HSCs allows a further 5-fold enrichment of functional LT-HSCs. ..
  3. Aversa G, Carballido J, Punnonen J, Chang C, Hauser T, Cocks B, et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol. 1997;75:202-5 pubmed
    ..SLAM was found to be a high-affinity self-ligand mediating molecular and cellular homophilic interactions. In this review we discuss SLAM as a receptor involved in T cell expansion and in directing immune responses to a Th0-Th1 pathway. ..
  4. Bispo da Silva A, Cerqueira Coelho P, Alves Oliveira Amparo J, Alves de Almeida Carneiro M, Pereira Borges J, dos Santos Souza C, et al. The flavonoid rutin modulates microglial/macrophage activation to a CD150/CD206 M2 phenotype. Chem Biol Interact. 2017;274:89-99 pubmed publisher
    ..These results point this flavonoid as a possible alternative in the treatment or prevention of neurodegenerative disorders. ..
  5. Gordiienko I, Shlapatska L, Kholodniuk V, Sklyarenko L, Gluzman D, Clark E, et al. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. PLoS ONE. 2017;12:e0185940 pubmed publisher